Eric Lefkofsky: Using His Fortune to Fight Cancer

About Eric

Eric Lefkofsky is currently ranked at #1275 in the world’s billionaires’ list by Forbes with a net worth of $1.88 billion. He has amassed a significant percentage of his fortune from technology-based start-ups. Eric Lefkofsky is the honcho at Groupon, 2010’s fastest growing entity, according to Forbes.

He has also worked in numerous prominent firms over his long career.

Moreover, Lefkofsky is an active contributor to the fight against cancer as well as a passionate humanitarian.

Educational background

South Field Lathrup High was where Eric received his secondary education. He attained his undergraduate BA degree from the University of Michigan. Eric later went to the Law school of the same university, where he was awarded Juris Doctor in 1993 click here.

Accelerated Disruption

The book is an editorial masterpiece written by Eric. The primary subject matter covered is the bringing of entrepreneurial ideas into fruition. This piece is a step-by-step guide for successful businesses. Right from the first page, the book explains how to overcome obstacles as well as how you can transform your business into a client magnet. Additionally, it enlightens employers on how to treat their workers for best output.

Tempus Inc.

Over the years, Eric has displayed unrivaled commitment in the fight against cancer. Not only has he poured a significant amount of dollars towards the cause, but he also inaugurated Tempus Inc., an enterprise whose sole objective is to eradicate this menace.

Tempus is transforming the approach taken in diagnosing cancer. Rather than following conventional methods, the firm uses genetics to establish the extent of the disease. Genetic samples from patients are run through high-end laboratory infrastructure after which personalized medication is given to every client. The company uses modernized lab equipment to enhance the credibility of the test results.

Philanthropy

Eric has been involved in humanitarian causes since 2006 when he started his family foundation. The organization’s objective is to alleviate living standards of the impoverished. Over the years, the charity has supported numerous causes across the country, particularly the terminally ill, with a bias towards cancer patients, contact him.

Additionally, the group runs a mentorship program, named Moneythink. This incentive seeks to educate the youth on various financial issues.

Clay Siegall & The Future of Cancer Fighting Biotechnology

When it comes to illnesses in today’s society, Cancer is one of the worlds most prevalent diseases. These deadly cells can manifest and grow throughout the years in the human in areas such as lungs, pancreas, liver, throat, etc. There have been many treatments for cancer, but none of them has really made a large enough dent to in saving lives. As of 2016, cancer treatment is far more advanced and precise. Antibody Based Therapies are some of the most successful treatments for fighting the illness and destroying the dangerous cells on contact. One of the leading Biotech Companies in the world is Seattle Genetics and this company is changing the current status quo.

Seattle Genetics stands out from the competitors thanks to it’s advanced cancer fighting capabilities, scientific innovation, development, and commercialization of medications. Seattle Genetics has one of the best leaders in the industry as well and it’s his guidance that has pushed the organization to the apex of the field. Clay Siegall is his name and eradicating cancer is his game. This doctor/scientist has knowledge, know-how, expertise, and skill to get the job done and he has a long resume of success to back up all claims. The George Washington University and University of Maryland Graduate has extensive education as Siegall holds a Ph.D in Genetics and a (BS) in Zoology. On top of that, the good doctor holds at least 15 patents of his own and is the author of more than 70 publications. Clay Siegall’s leadership and experience in the game is what help makes him so valuable.

The company’s flagship medicine (ADCETRIS) is one of the most successful at fighting cancerous cells within the body. With this success, the medicines are now available in over 60 countries worldwide. As of the year 2016, Seattle Genetics’ net worth is estimated at $4.7 Billion and Dr. Clay Siegall is in firm control as he continues to steer the ship to future success.When it comes to illnesses in today’s society, Cancer is one of the worlds most prevalent diseases. These deadly cells can manifest and grow throughout the years in the human in areas such as lungs, pancreas, liver, throat, etc. There have been many treatments for cancer, but none of them has really made a large enough dent to in saving lives. As of 2016, cancer treatment is far more advanced and precise. Antibody Based Therapies are some of the most successful treatments for fighting the illness and destroying the dangerous cells on contact. One of the leading Biotech Companies in the world is Seattle Genetics and this company is changing the current status quo.

The company’s flagship medicine (ADCETRIS) is one of the most successful at fighting cancerous cells within the body. With this success, the medicines are now available in over 60 countries worldwide. As of the year 2016, Seattle Genetics’ net worth is estimated at $4.7 Billion and Dr. Clay Siegall is in firm control as he continues to steer the ship to future success.

Eric Lefkofsky and His Tempus Role

Eric Lefkofsky is the CEO and founder of Tempus. Under his auspices this
technology company has built an operating system to battle cancer.This company through its research allows physicians to personalize the care of their cancer patient.
What Eric Lefkofsky has done is to found a company which is researching ways of treating cancer. Why did he do this? It stemmed from watching a family member
being treated for this terrible disease. His goal was to bring new and innovative technology to the doctors who are in the front lines treating these patients.
Tempus analyzes data so that physicians have real time data to treat their patients based on analytics drawn from other cancer patients. They are trying to build precision oncology.
Tempus has built software that physicians can utilize and obtain information so they can treat their patients better without having to waste all of their time researching answers.
Tempus has created this software to make the physicians work easier . This allows the doctor more time with the patient and less time comparing data that may be out there.

Tempus is not the only endeavor where Eric Lefkofsky is involved. He also wrote a book which he called “Accelerated Disruption.” This is explained as how a business “misses the boat “by not realizing that “technology can allow a challenge to come from anywhere.This is what the book states. This book was written by Eric Lefkofsky . In it he expresses that in order to compete and to emerge and grow in the coming years they have to improve their technology. Also he stressed that the right companies need to be chosen to be innovated.
Eric Lefkofsky is not only the CEO of Tempus but he is a trustee in many other
organizations like the Lurie’s Children’s Hospital of Chicago,The Steppenwolf Theatre. Eric Lefkofsky”s philanthropic endeavors reach to wide domains, He even has started a foundation with his wife. It is called the Lefkofsky Family Foundation.
This foundation has under its umbrella many businesses and schools .Under Education the schools that are under this part of the umbrella ,each has a different thing that they bring to the table to enhance a child’ Another facet under this umbrella is human rights. It incorporates such companies as The Human Rights Watch and The Jewish United Fund . Both have human rights in their scope of
practice.
The world is a better place for having Eric Lefkofsky in it because he uses his entrepreneurial skills to make a better world. And his later skills have proven to benefit mankind in the best possible way. He founded a company which is working diligently to help rid the world of cancer.
They are doing this by testing patient’s blood and arriving at the conclusion of what genotypes can make a person more prone to getting cancer in their lifetime and what type. Then they place this information on their software and send this information to physicians treating cancer in their patients. Eric Lefkofsky,entreprenuer extraordinaire.

Read more here:

http://faculty.chicagobooth.edu/eric.lefkofsky/portfolio.html